Trials / Recruiting
RecruitingNCT05968417
Myeloma Novel Drug Discovery Ver 1.2
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Institute of Cancer Research, United Kingdom · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational study - sample collection only. | No intervention - blood and/or bone marrow sample collection only |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2033-02-28
- Completion
- 2035-02-28
- First posted
- 2023-08-01
- Last updated
- 2023-08-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05968417. Inclusion in this directory is not an endorsement.